UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. ___)

Unicycive Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

90466Y103

(CUSIP Number)

June 26, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X]       Rule 13d-1(b)

[X]       Rule 13d-1(c)

[ ]       Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b) X

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b) X

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b) X

3. SEC Use Only

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b) X

________________________________________________________________________

Logos Global is the investment adviser to investment funds, including Opportunities Fund. Logos GP is the general partner of Opportunities Fund. Logos Global GP is the general partner of Logos Global. Dr. William is a control person of Logos Global and Logos GP.

The Filers are filing this statement jointly but not as members of a group, and they expressly disclaim membership in a group. In addition, filing this Schedule 13G on behalf of Opportunities Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

See Items 5-9 and 11 of the cover page for each Filer.

The percentages reported in this Schedule 13G are based on 34,754,401 shares of Common Stock outstanding as of November 14, 2023, as disclosed in the Form 10-Q filed by the Issuer on November 14, 2023. The shares of Common Stock held by the reporting persons consist of (1) 3,469,927 shares of Common Stock, (2) 1,359,000 shares of Common Stock issuable on conversion of shares of Series A-2 Convertible Preferred Stock of the Issuer (“Series A-2 Stock”), (3) 3,658,278 shares of Common Stock issuable on conversion of shares of Series A-3 Convertible Preferred Stock of the Issuer (“Series A-3 Stock”) that are issuable pursuant to Tranche A Warrants issued by the Issuer, (4) 3,325,707 shares of Common Stock issuable on conversion of shares of Series A-4 Convertible Preferred Stock of the Issuer (“Series A-4 Stock”) that are issuable pursuant to Tranche B Warrants issued by the Issuer, and (5) 5,321,131 shares of Common Stock issuable on conversion of shares of Series A-5 Convertible Preferred Stock of the Issuer (“Series A-5 Stock”) that are issuable pursuant to Tranche C Warrants issued by the Issuer. The Series A-2 Stock, Series A-3 Stock, Series A-4 Stock and Series A-5 Stock are subject to a beneficial ownership limitation that prevents such stock from converting if such conversion would result in the reporting persons’ beneficial ownership of the Common Stock to exceed 9.99% .

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Opportunities Fund holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

Not applicable.

Not applicable.

Not applicable.

Certification of Logos Global, Logos Global GP and Dr. William:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Certification of Opportunities Fund and Logos GP:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 22, 2024

EXHIBIT A

AGREEMENT REGARDING JOINT FILING
OF STATEMENT ON SCHEDULE 13D OR 13G

The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Logos Global Management LP, a Delaware limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Act, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

Dated: January 22, 2024